The use of mycophenolate mofetil in treating patients with non responding aplastic anemia
Aplastic anemia is a relatively uncommon disease and conventional management options include immunosuppressive drugs and/or haematopoeitic stem cell transplantation. It is now known that the pathogenesis of aplastic anemia is immune mediated. Mycophenolate mofetil is a common immunosuppressive drug...
Autori principali: | Gan, Gin Gin, Leong, C.F., Sangkar, J.V., Teh, A., Goh, K.Y., Cheong, S.K. |
---|---|
Natura: | Articolo |
Lingua: | English |
Pubblicazione: |
Malaysian Medical Association
2005
|
Soggetti: | |
Accesso online: | http://eprints.um.edu.my/24590/1/Aplastic_Anemia.pdf |
Documenti analoghi
Documenti analoghi
-
Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship.
di: Rook, M, et al.
Pubblicazione: (2006) -
Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
di: Moore, R, et al.
Pubblicazione: (2006) -
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
di: Flechner, S, et al.
Pubblicazione: (2005) -
Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review
di: Knight, S, et al.
Pubblicazione: (2008) -
Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review.
di: Knight, SR, et al.
Pubblicazione: (2009)